DRAFT 12

Vilnius International Summit on Communicable Diseases

June 26 (Sunday)

Research session “VIRUSES AS MOVING TARGETS”

13th Annual Conference of Baltic Antiviral Network (BAN)

Location: LithuanianAcademy of Science, Gedimino Av. 3, Vilnius, Lithuania

(Working language English)

Session I: VIRAL EVOLUTION (morning)

Key-note speakers:

  • Divergent and convergent theories of viral evolution, and the reality. Yuri Khudyakov (CDC, Atlanta, USA)
  • Patterns of HIV evolution in Europe (different strains in different risk groups; different evolution rate in different risk groups/transmission routes; emergence of new strains).Vladimir Lukashov (University of Amsterdam, Holland)
  • HIV recombination patterns and implications for disease progression. Patrik Medstrand (University of Lund, Sweden)

Abstract driven (oral and poster) presentations:

Session II: VIRUSES AND IMMUNE ESCAPE (afternoon)

Key-note speakers:

  • Mechanisms and outcomes of immune escape in HCV infection.Agata Budkowska (Pasteur Institute, France)
  • Mechanisms of immune escape in HBV infection and vaccine failure. Saleem KamiliandJan Drobeniuc (CDC, Atlanta, USA)

Abstract driven (oral and poster) presentations:

Session III: EPIDEMIOLOGY, SOCIAL AND BEHAVIOUR ASPECTS (afternoon)

Key-note speakers:

  • SIALON 2 project results. Lorenzo Gios (Italy, TBC)
  • Knowledge Of Human Papillomavirus and Vaccination Among Students Of Secondary Schools In Kaunas City.Augusta Petrušaitė (Lithuanian University of Health Sciences, Kaunas, Lithuania)

Abstract driven (oral and poster) presentations:

June 27 (Monday)

Research session “VIRUSES AS MOVING TARGETS” (cont.)

13th Annual Conference of Baltic Antiviral Network (BAN)

Location: LithuanianAcademy of Science, Gedimino Av. 3, Vilnius, Lithuania

(Working language English)

Session III: MECHANISMS OF VIRAL PATHOGENESIS (morning)

Key-note speakers:

  • HIV-1 induced impairment of B-cell functions. Francesca Chiodi (Karolinska Institutet, Sweden)
  • Mechanisms of metabolic reprogramming in viral infection. Birke Bartosch (INSERM, Lyon, France)
  • Role of human papilloma virus in development of cervical ca in situ. Joana Celiešiūtė(Lithuanian University of Health Sciences, Kaunas, Lithuania)
  • Oncogenic potential of hepatitis C virus antigens. Ranjit Ray (St Louis University School of Medicine, US)

Abstract driven (oral and poster) presentations:

Session IV: NEW AND RE-EMERGING INFECTIONS (afternoon)

Key-note speakers:

  • New Flaviviruses, threats and possibilities of prevention. Karl Ljungberg (Karolinska Institutet, Sweden)
  • The immune response and within-host emergence of pandemic influenza virus//Risks of evolution towards novel pandemic influenza A virus.Albertus D Osterhaus (Erasmus Medical Centre, Rotterdam, Netherlands; Artemis One Health Research Foundation, Utrecht, The Netherlands; Centre for Infection Medicine and Zoonosis Research, University of Veterinary Medicine, Hanover, Germany)
  • Newly identified viruses in human gastroenteritis. Albertus D Osterhaus(Erasmus Medical Centre, Rotterdam, Netherlands; Artemis One Health Research Foundation, Utrecht, The Netherlands; Centre for Infection Medicine and Zoonosis Research, University of Veterinary Medicine, Hanover, Germany)
  • Human herpes viruses in individuals with unspecified encephalopathy. Modra Murovska (Riga Stradins University, Latvia)
  • Ten lessons for the next influenza pandemic. Fleming DM and Durnall H (Royal College of General Practitioners, Research and Surveillance Centre, Birmingham, UK. )

Abstract driven (oral and poster) presentations:

Session V: VACCINES AND VACCINE PREVENTABLE DISEASES (afternoon)

Key-note speakers:

  • Development of viral vaccines: vaccines against HCV. Lars Frelin (Karolinska Institutet, Stockholm, Sweden)
  • Qualitative survey of pregnant women‘s vaccination against flu. A. Strelcoviene (Lithuanian University of Health Sciences, Kaunas, Lithuania)
  • HIV-1 vaccines, perspectives of the development. Britta Wahren (Karolinska Institutet, Sweden)
  • Preliminary results of clinical trial of 2nd phase therapeutical vaccine against HIV.Andrej Kozlov (Russia)

Abstract driven (oral and poster) presentations:

June 28 (Tuesday)

Research session “VIRUSES AS MOVING TARGETS” (cont.)

13th Annual Conference of Baltic Antiviral Network (BAN)

Location: Lithuanian Academy of Science, Gedimino Av. 3, Vilnius, Lithuania

Session V: CLOSED SESSION OF BAN NETWORK (morning)

June 28 (Tuesday)

Education session (lectures from outstanding specialists)

Location: Hotel „Karolina“, Sausio 13-osios St. 2, Vilnius, Lithuania

(Working languages English and Lithuanian with simultaneous translation)

Session I: VACCINE PREVENTABLE AND ENTERITIC DISEASES (morning)

Key-note speakers:

  • Polio eradication: final steps in Europe and the world. Vytautas Usonis (Vilniusuniversity, Lithuania)
  • Vaccination against MenB in UK: first lessons of universal vaccination. (NHS representative, UK)
  • Progress of vaccination against flu in pregnant women in frame of WHO project.Prof. Rūta Nadišauskienė (Lithuanian University of Health Sciences, Kaunas, Lithuania)
  • Tick-borne encephalitis.Prof. Auksė Mickienė (Lithuanian University of Health Sciences, Kaunas, Lithuania)
  • HPV role in secondary prevention of cervical cancer (testing of HPV for screening, diagnostis and observation). Prof. Daiva Vaitkienė (Lithuanian University of Health Sciences, Kaunas, Lithuania)
  • HPV vaccination from autumn – do we expect success (primary prevention). Dr. Kristina Jarienė (Lithuanian University of Health Sciences, Kaunas, Lithuania)
  • Analysis of hepatitis A outbreaks in Europe. Anders Widell (Lund University, Sweden)
  • Hepatitis A virus. Anders Widell (Lund University, Sweden)
  • Hepatitis E virus.Jan Drobeniuc (CDC. Atlanta, US)
  • We need one general talk on VB!!!!!!!!!!!!!!!

Abstract driven (oral and poster) presentations:

Session II: PUBLIC HEALTH AND SOCIAL DETERMINANTS OF COMMUNICABLE DISEASES (afternoon)

Key-note speakers:

  • Risk communication. (WHO Euro representative)
  • Psychological vaccination aspects. Prof. Eugenijus Laurinaitis (Vilnius university, Lithuania)
  • Zika virus infection (?). Karl Ljungberg (??)
  • Drug users help system: from primary prevention to early intervention, treatment and reintegration.Inga Juozapavičienė (Drug, Tobacco and Alcohol Control Department, Lithuania)
  • Communicable Diseases and drug user social rehabilitation and integration. (Representative of social rehabilitation institution (community) in Lithuania)
  • Stages of support for drug users. Robertas Badaras (Vilnius university, Lithuania)
  • San-Patrignano presentation ?
  • Prison health issues (?)

Abstract driven (oral and poster) presentations:

Session III: LABORATOTY DIAGNOSTICS AND CARE OF COMMUNICABLE DISEASES (afternoon)

Key-note speakers:

  • Approaches to the studies of viral evolution. Yuri Khudyakov (CDC. Atlanta, US)
  • Significance of perinatal infection diagnostic and treatment. Prof. Meilė Minkauskienė (Lithuanian University of Health Sciences, Kaunas, Lithuania)
  • Present and future of communicable diseases laboratory diagnostic (?) Saleem Kamili (CDC, Atlanta, US)
  • New developments in STI diagnostic. Magnus Unemo (Sweden)
  • Laboratory quality management, QA/QC issues.Jan Drobeniuc (CDC, Atlanta, USA)
  • Blood safety issues (?)
  • Apie kraujo komponentų apsaugojimą nuo zika ir kitų egzotinių, šiuo metu netiriamų Lietuvoje virusų.

Abstract driven (oral and poster) presentations:

June 29 (Wednesday)

Education session (lectures from outstanding specialists) (cont.)

Location: Hotel „Karolina“, Sausio 13-osios St. 2, Vilnius, Lithuania

(Working languages English and Lithuanian with simultaneous translation)

Session IV: HIV AND ASSOCIATED INFECTIONS AND CONDITIONS (morning)

Key-note speakers:

  • ND presentation (?). Ali Arsalo (Finland)
  • HIV-1, HBV, HCV: Epidemiological Situation in Baltic Countries. Tatjana Tallo (The Public Health Agency of Sweden, Stockholm, Sweden)
  • Diagnostics of HIV-1 infection, and failure to prevent (title to be confirmed). Prof.Saulius Caplinskas (Centre for Communicable Diseases and AIDS, Lithuania)
  • Immunobiology of HIV-1 infection. Francesca Chiodi (Karolinska Institutet, Sweden)
  • Opportunistic infections in immunosuppressed. Annelie Brauner (Karolinska Institutet, Sweden)
  • Possibilities to prognose the course of HIV infection and the efficacy of ART.Maria Bobkova (NF Gamaleya Research Centre of Epidemiology and Microbiology, Moscow, Russia)
  • Burden of TB - HIV co-infections in St. Petersburg. (doctor from St. Petersburg TB hospital)

Abstract driven (oral and poster) presentations:

Session V:PARENTERALLY TRANSMITTED AND HEALTH CARE ASSOCIATED INFECTIONS (afternoon)

Key-note speakers:

  • Analysis of nosocomial infections with blood-borne viruses (example of HCV) Anders Widell (Lund University, Sweden) OR
  • Nosocomial infection in hospital settings - emerging problems with multiresistant microbes.Johannes Hallauer (Germany)
  • Nosocomial infections in Latvia. Jurij Perevodcikov (Latvia)
  • Children long-living with HIV in Romania. Mariana Mardarescu (Romania)
  • Hepatitis B Virus.Karen Kuyrigyan (Chumakovs Insitute of Poliomyelitis and Viral Encephalitides, Moscow, Russia)
  • Hepatitis C Virus. Maria Issaguliants (Karolinska Institutet, Sweden, and Riga Stradins University, Latvia)
  • Hepatitis D Virus.Mikhail Mikhailov (Chumakovs Insitute of Poliomyelitis and Viral Encephalitides, Moscow, Russia)
  • We need one general talk on VB!!!!!!!!!!!!!!!
  • HCV elimination programme in Georgia.Natalie Bolokadze (Georgia)

Abstract driven (oral and poster) presentations:

June 30 (Thursday)

Networking and Activity Coordination session“How to do right things right”

Location: Government House, Gedimino Av. 11, Vilnius, Lithuania

(Working languages English and Lithuanian with simultaneous translation)

Plenary session I: (morning)

  • Euro Commissioner Vytenis Andriukaitis
  • Minister of Health of the Republic of Lithuania
  • Communicable diseases situation review. (WHO and ECDC, TBC)
  • Programme modifications of universal immunisation schedule: introduction of new vaccines and solution of delivery problems. (ECDC representative)
  • Communication role for vaccination coverage. (WHO representative or TBC)

Plenary session II: (morning)

  • Cost of communicable diseases. (National Health Fund representative, Lithuania)
  • Psychological vaccination aspects. Prof. Eugenijus Laurinaitis (Vilnius university, Lithuania)
  • Diseases awareness campaigns to effectively implement immunisation against HPV strategies: Finish experience.(THL representative, Finland)
  • New challenges in control of infections by migration and refugees. Johannes Hallauer (Germany)

Plenary debate session I “Role of general practitioner and opportunities in communicable diseases management” afternoon)

Panelists:

  • Development of the national immunoprophylaxis programme in Lithuania: where will we go?(MoH representative, or Vytautas Usonis) (Vilnius university, Lithuania)
  • Vytautas Kasiulevičius (??)
  • Leonas Valius (Lithuanian University of Health Sciences, Kaunas, Lithuania)
  • ......

Plenary debate session II “Challenges of general population and target groups health literacy”(afternoon)

Panelists:

  • ......

July 1 (Friday)

Networking and Activity Coordination session “How to do right things right”

Location: Government House, Gedimino Av. 11, Vilnius, Lithuania

(Working languages English and Lithuanian with simultaneous translation)

Plenary session I: (morning)

  • EC, WHO, ECDC, UNAIDS representatives
  • Prevalence of HIV and viral hepatitis among PWID in European context.(EMCDDA representative)
  • Communicable diseases in UNESCO global education strategy. (UNESCO representative, TBC)
  • Strengthening TB diagnosis and treatment endorsing WHO End TB strategy after 2015.Dr. Vaira Leimane (TB WHO Collaborating Centre, Latvia)

Plenary session II: (morning)

  • Northern Dimension Partnership representative. Ali Arsalo (Finland)
  • Primary drug use prevention – best way to prevent drug use related communicable diseases. Jon Sigfusson (Island)
  • Intervention effectiveness to prevent HCV among people who inject drugs.Peter Vickerman (BristolUniversity)

Plenary debate session III “The ways to reduce burden of socially important communicable diseases”(afternoon)

Panelists:

  • Quality in HIV prevention (How to do right things right?). Viveca Urwitz (Sweden or TBC)
  • AIDS: lessons learnt and challenges in Lithuania. Saulius Čaplinskas (Lithuania)
  • HCV elimination programme in Georgia. Natalie Bolokadze (Gruzija)
  • Verification of elimination of HIV MTC and congenital syphilis? Lali Kothenashvili (WHO, TBC)
  • Inga Juozapavičienė (Drug, Tobacco and Alcohol Control Department, Lithuania)
  • Gediminas Černiauskas (?)
  • .....

Closing session (afternoon)

1